Vijlak Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.75 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.75 Cr
as on 11-12-2024
- Company Age 36 Year, 10 Months
- Last Filing with ROC 31 Mar 2013
- Open Charges ₹ 151.75 Cr
as on 11-12-2024
About Vijlak Pharma
The Corporate was formerly known as Vij Lak Engineers Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2013. It's a company limited by shares with an authorized capital of Rs 1.75 Cr and a paid-up capital of Rs 1.75 Cr.
The company currently has active open charges totaling ₹151.75 Cr.
Sudhakar Chadalavada, Anil Kunam, Kunam Rajani, and One other member serve as directors at the Company.
- CIN/LLPIN
U25209TG1988PLC008288
- Company No.
008288
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Feb 1988
- Date of AGM
25 Jul 2013
- Date of Balance Sheet
31 Mar 2013
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Vijlak Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghava Kunam  | Managing Director | 23-Feb-2009 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sudhakar Chadalavada | Director | 02-Mar-2009 | Current |
| Anil Kunam | Director | 02-Mar-2009 | Current |
| Kunam Rajani | Director | 23-Feb-2009 | Current |
Financial Performance of Vijlak Pharma.
Enhance accessibility to Vijlak Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Vijlak Pharma?
Unlock access to Vijlak Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 08 Dec 2010 | ₹12.15 Cr | Open |
State Bank Of India Creation Date: 29 Jan 2010 | ₹131.00 Cr | Open |
State Bank Of India Creation Date: 20 Dec 1997 | ₹8.60 Cr | Open |
How Many Employees Work at Vijlak Pharma?
Unlock and access historical data on people associated with Vijlak Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vijlak Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vijlak Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
